Phase 2 placebo-controlled randomized trial of itepekimab in non-cystic fibrosis bronchiectasis

Phase 2, randomised, double-blind trial in bronchiectasis comparing Itepekimab every 2 weeks, Itepekimab every 4 weeks with alternating placebo and Placebo every 2 weeks (3 arms). Primary endpoint: Recurrence of pulmonary exacerbation events. Planned start Mar 2024; status: not yet recruiting.